# Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

> **NCT02465268** · PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 175 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Malignant Glioma
- Astrocytoma, Grade IV
- GBM

## Interventions

- **BIOLOGICAL:** pp65-shLAMP DC with GM-CSF
- **BIOLOGICAL:** unpulsed PBMC and saline
- **DRUG:** Td
- **DRUG:** Saline
- **BIOLOGICAL:** pp65-flLAMP DC with GM-CSF

## Key facts

- **NCT ID:** NCT02465268
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-09
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465268, "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02465268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*